(Q64110569)

English

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group s

scientific article published on 04 April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

based on heuristic

phase II clinical trial

1 reference

based on heuristic

gynecologic oncology

1 reference

based on heuristic

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Ronald D Alvarez

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Michael W Sill

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Susan A Davidson

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Carolyn Y Muller

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

David P Bender

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Robert L DeBernardo

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Warner K Huh

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

language of work or name

0 references

publication date

4 April 2014

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

133

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

433-438

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Immunotherapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.571

7 January 2021

Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24708919

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24708919

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.YGYNO.2014.03.571

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24708919%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64110569&oldid=1756326801"